The Claim
Administration of rapamycin initiated at 270 days of age (mid-life) is significantly associated with reduced mortality risk in male and female mice, based on interim analysis, indicating potential efficacy when treatment begins prior to old age.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Scientists gave mice a drug called rapamycin when they were middle-aged (around 270 days old) and found that both male and female mice lived longer compared to mice that didn't get the drug.
See the scientific wording
Rapamycin initiated at 270 days of age (mid-life) is associated with significantly reduced mortality risk in both male and female mice based on interim analysis, suggesting efficacy even when treatment begins before old age.
What the research says
1 studyStudy: Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
The study tested giving rapamycin to mice starting at 270 days old (middle age) and found it helped them live longer, based on an early analysis. This matches exactly what the claim says about rapamycin at 270 days reducing death risk in both male and female mice.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.